The results of 2 randomized controlled trials showed that filgotinib improved quality of life when given in combination with methotrexate or as monotherapy in rheumatoid arthritis.
Fibromyalgia, osteoarthritis, sciatic syndrome, rheumatoid arthritis, and moderate depression may be more prevalent in working-age individuals with vs without migraine.
Consensus recommendations on the use of biosimilars for the treatment of patients with rheumatologic diseases were recently published in Annals of the Rheumatic Diseases.
Ketoprofen was found to be effective in relieving moderate to severe pain in patients with rheumatoid arthritis.
Although a majority of women with rheumatoid arthritis were previously though to achieve remission during pregnancy, recent studies indicate remission occurs in only 20% to 40% of cases.
In patients with rheumatoid arthritis, vitamin D deficiency was shown to be associated with increased neuropathic pain.
Tocilizumab was associated with significant improvements in hemoglobin and hematocrit over 2 years of treatment in patients with rheumatoid arthritis.
For patients with chronic fatigue syndrome/fibromyalgia or rheumatoid arthritis, morphine has anti-hyperalgesic effects comparable with placebo.
Increased baseline gene expression in peripheral blood may be associated with improved clinical response to methotrexate in rheumatoid arthritis.
A sizeable percentage of patients with rheumatoid arthritis who are in clinical remission have evidence of disease activity on magnetic resonance imaging of the foot that is mostly affected.
Longitudinal opioid prescribing patterns suggest that regular use among patients with rheumatoid arthritis (RA) is slightly declining.
Peripheral anti-IL-6 cytokine treatment is associated with improvement in depressive symptoms in patients with RA.
MRI may assist in identifying patients with unclassified arthritis who will develop rheumatoid arthritis (RA) — primarily in patients with UA presenting with oligoarthritis.
Approximately 1 in 3 patients with RA who discontinued tofacitinib maintained low disease activity after 1 year.
A high prevalence and risk for metabolic syndrome was found in patients with rheumatoid arthritis.
The FDA has approved Renflexis, the second approved biosimilar to Remicade.
Patients with RA suffering from S. aureus infection have more complications and higher mortality rates than patients without RA.
EULAR recommendations were updated for rheumatoid arthritis management to include new guidelines on starting effective therapy in patients early.
No evidence was found of a higher cardiovascular risk among rheumatoid arthritis patients who switched from a different biologic drug or tofacitinib to tocilizumab vs to a tumor necrosis factor inhibitor.
Urinary proteomics may help identify biomarkers that can distinguish between different types of inflammatory arthritis.
Early identification and treatment of patients with RA is central to successfully limiting joint damage and disease progression.
Telerheumatology can improve healthcare access, patient outcomes, and costs
No statistically significant association was found between MTX or anti-TNF use and breast cancer recurrence.
Knee OA was associated with cortical thinning in brain regions not typically associated with pain processing.
MBDA scores combined with ACPA testing allowed researchers to predict RA relapse in more than 80% of patients.
"Based on our 2 study populations, individuals with chronic pain experienced more severe depressive, anxiety, and stress symptoms compared to those with chronic RA."
Age and cigarette smoking are associated with inflammatory joint signs in a high-risk cohort of RA first-degree relatives.
The Short-Form Health Survey as an Effective Diagnostic Tool for Psychiatric Comorbidities in RA PatientsAugust 02, 2016
The analysis found that the SF-36 survey was an effective diagnostic tool for MDD and GAD in patients with RA.
Assessing epidemiologic and genetic factors among individuals with positive family history of RA may identify those suitable for RA prevention strategies
The heterogeneity of RA pathologic processes renders development of adapted treatments challenging, calling for a better understanding of location-specific disease mechanisms.
Clinical Pain Advisor Articles
- Reviewing the Efficacy, Safety, and Tolerability of Cannabis-Based Medicines for Chronic Neuropathic Pain
- Femoral Nerve Block Alone or in Combination With Sciatic Nerve Block for TKA: A Meta-Analysis
- Tackling the Chronic Pain and Opioid Use Disorder Crises Through Public-Private Partnerships
- How the City of San Francisco Is Tackling the Intertwined HIV/HCV and Opioid Epidemics
- Pain Tolerance in Buprenorphine Maintenance Treatment
- Radiofrequency Ablation for Chronic Hip Pain: Reviewing the Evidence
- Opioid Use Disorder Treatment: Evidence-Based Guideline
- Betel Quid Addiction and Implications for Substance Use Disorder
- Low Back Pain: Contributing Factors, Prophylactic Strategies, and Effective Treatments
- Peripherally Acting Opioid and Cannabinoid May Be Effective for Neuropathic Pain
- Transcranial Magnetic Stimulation May Prevent Migraine in Adolescents
- Widespread Impact of Reducing Opioids, Adding IV Acetaminophen for Postsurgical Pain Management
- GI Safety Compared for NSAIDs in Patients With Arthritis
- Opioid Prescribing Trends in Patients With, Without Cancer
- DOJ Rescinds Protections Afforded by Americans With Disabilities Act